eligibility_summary
Inclusion: Adults (≥18) with UICC stage IV mCRC not suitable for local therapy, ECOG ≤2, failed/intolerant to FP, oxaliplatin, irinotecan, no irinotecan in 6 mo (or prior response if >6 mo), measurable RECIST 1.1 lesion, consent, WOCBP: negative test + dual contraception, fertile men: dual contraception. Exclusion: hypersensitivity, recent trials/therapy or unresolved ≥G2 AEs, SN-38–interacting meds, active second cancer, NYHA ≥III, active infection/HIV/HBV/HCV viremia, inadequate labs, MSI-H/dMMR, pregnancy/lactation, unfit/unable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Sacituzumab govitecan (SG) vs physician’s choice standard therapy. SG is an antibody–drug conjugate (ADC): a humanized anti–Trop‑2 monoclonal antibody linked to SN‑38, the active metabolite of irinotecan and a topoisomerase I inhibitor (cytotoxic chemotherapy). Mechanism: SG binds Trop‑2 on tumor cells, is internalized, and releases SN‑38 to inhibit topoisomerase I, causing DNA damage and apoptosis, a bystander effect can kill adjacent cells. Targets: Trop‑2–expressing colorectal cancer cells and the DNA topoisomerase I pathway (S‑phase). Comparator targets depend on physician choice (guideline‑based options).